首页> 外文期刊>Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases >Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naive individuals in Cambodia, Thailand and Vietnam: An ANRS AC12 working group study
【24h】

Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naive individuals in Cambodia, Thailand and Vietnam: An ANRS AC12 working group study

机译:柬埔寨,泰国和越南的ARV初次感染者HIV-1 CRF01_AE整合酶编码区的自然多态性:ANRS AC12工作组研究

获取原文
获取原文并翻译 | 示例
       

摘要

The HIV integrase enzyme is essential for the HIV life cycle as it mediates integration of HIV-1 proviral DNA into the infected cell's genome. Recently, the development of drugs capable of inhibiting integrase has provided major new options for HIV-infected, treatment-experienced patients with multidrug resistant virus, as well treatment-naive patients. More than 40 amino acid substitutions within integrase have been described as associated mostly with resistance of HIV B-subtypes to currently available integrase inhibitors (INIs). We have analyzed the natural polymorphisms of the integrase coding region in 87 anti retroviral-naive subjects (32 from Cambodia, 37 from Thailand and 18 from Vietnam) infected with CRF01_AE virus, the predominant HIV-1 strain circulating in Southeast Asia. The 864 bp integrase coding region was sequenced using the ANRS consensus sequencing technique from plasma samples, and amino acid results were interpreted for drug resistance according to the ANRS (Updated July 2009, version 18) and Stanford algorithms (Version November 6, 2009). Alignment of the 87 amino acid sequences against the 2004 Los Alamos HIV-1 clade B consensus sequence showed that overall, 119 of 288 (41.3%) amino acid positions presented at least one polymorphism each. Substitutions found in >60% of study subjects occurred at: K14, A21, V31, S39,172, T112, T124, T125, G134, 1135, K136, D167, V201, L234 and S283. Also, new amino acid substitutions of as yet unknown significance were identified: E152K/H, S153F/L, N1551 and E157G. None of the known integrase resistance mutations were observed, except E157Q found in one Cambodian subject (1.1%, CI 95% 0.02-6.3%). The clinical impact of this substitution on resistance of B and nonB-viruses to the licensed INI raltegravir is unclear. If this substitution is confirmed to compromise the virologic response to raltegravir, further studies will be needed to better assess the prevalence of this substitution among CRF01_AE virus
机译:HIV整合酶对于HIV生命周期至关重要,因为它介导HIV-1前病毒DNA整合到受感染细胞的基因组中。最近,能够抑制整合酶的药物的开发为HIV感染的,具有治疗经验的多药耐药性病毒患者以及未接受过治疗的患者提供了重要的新选择。整合酶中超过40个氨基酸取代已被描述为主要与HIV B亚型对目前可用的整合酶抑制剂(INI)的抗性有关。我们已经分析了感染CRF01_AE病毒(东南亚流行的主要HIV-1病毒)的87位抗逆转录病毒天真受试者(32名来自柬埔寨,37名来自泰国和18名来自越南)的整合酶编码区的自然多态性。使用ANRS共有测序技术从血浆样品中测序864 bp的整合酶编码区,并根据ANRS(2009年7月更新,版本18)和Stanford算法(2009年11月6日版本)解释氨基酸结果的耐药性。 87个氨基酸序列与2004年Los Alamos HIV-1进化枝B共有序列的比对显示,总体而言,288个氨基酸位置中的119个(占41.3%)每个都有至少一种多态性。在> 60%的研究对象中发现的替换发生在:K14,A21,V31,S39,172,T112,T124,T125,G134、1135,K136,D167,V201,L234和S283。此外,还鉴定出了尚不重要的新氨基酸取代:E152K / H,S153F / L,N1551和E157G。除了在一名柬埔寨受试者中发现E157Q外,没有观察到已知的整合酶抗性突变(1.1%,CI 95%0.02-6.3%)。目前尚不清楚这种替代对B和非B病毒对获得许可的INI raltegravir的耐​​药性的临床影响。如果确认这种替代会损害对raltegravir的病毒学应答,则需要进一步研究以更好地评估CRF01_AE病毒中这种替代的患病率

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号